Amplia Therapeutics Limited
ASX:ATX.AX
0.15 (AUD) • At close October 23, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Amplia Therapeutics Limited |
Symbool | ATX.AX |
Munteenheid | AUD |
Prijs | 0.15 |
Beurswaarde | 41,219,700 |
Dividendpercentage | 0% |
52-weken bereik | 0.055 - 0.18 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Christopher J. Burns B.Sc., BSc(Hons), Ph.D. |
Website | https://www.ampliatx.com |
An error occurred while fetching data.
Over Amplia Therapeutics Limited
Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for oncology and chronic fibrosis in Australia. The company's product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other cancers and fibrotic diseases indications, that has
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (AUD)
Cijfers zijn in miljoenen (AUD)